Generic drugmaker Actavis Plc (ACT.N) said it would acquire specialty pharmaceuticals company Forest Laboratories Inc (FRX.N) in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 percent to Forest’s Friday close. The offer comprises $26.04 […]